Skip to main content

Table 1 Patient Demographic and Clinical Characteristics

From: Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy

  Cohort (%) JIA (%) Other Associated Systemic Disease(%) Idiopathic (%)
No. of Patients 166 91 (54.8) 9 (5.4) 66 (39.8)
Female 99 (59.6) 62 (68.1) 2 (22.2) 35 (53)
Age at diagnosis
 Average 8.03y 5.9y 10.5y 10.7y
 Median 7y 5y 12y 11y
Referral type
 Tertiary 93 (56) 56 (61.5) 6 (66.7) 31 (47)
Ethnicity
 Caucasian 128 (77.1) 73(80.2) 6 (66.7) 49 (74.2)
 Asian 8 (4.8) 2 (2.2) 2 (22.2) 4 (6)
 African 1 (0.6) 0 0 1 (1.5)
 Other 7 (4.2) 2 (2.2) 1 (11.1) 4 (6)
 Unknown 22 (13.3) 14 (15.4) 0 8 (12.1)
Laterality on presentation
 Bilateral 116 (69.9) 62 (68.1) 5 (55.6) 49 (74.2)
Anatomic Localisation
 Anterior 125 (75.3) 89 (97.8) 5 (55.6) 31 (47)
 Intermediate 29 (17.5) 0 1 (11.1) 28 (42.4)
 Posterior 1 (0.6) 0 0 1 (1.5)
 Panuveitis 11 (6.6) 2 (2.2) 3 (33.3) 6 (9.1)
Visual Impairment at baseline (per eye)
  > 0.3logMAR 43 (18.4) 22 (18.6) 3 (27.3) 18 (17.1)
  ≥ 1.0 logMAR 10 (4.3) 7 (5.9) 0 3 (2.9)
Medication use over study
Corticosteroids
 Topical CS 155 (93.4) 91 (100) 8 (88.9) 56 (84.8)
 Systemic CS 58 (34.9) 28 (30.8) 7 (77.8) 23 (34.8)
 Peri/Intraocular 12 (7.2) 6 (6.6) 3 (33.3) 6 (9.1)
 Steroids
Conventional DMARD 121 (72.9) 82 (90.1) 6 (66.7) 33 (50)
 Methotrexate 121 (72.9) 82 (90.1) 6 (66.7) 33 (50)
 Only Methotrexate 47 (28.3%) 35 (38.5) 1 (11.1) 11 (16.7)
 Mycophenolate 36 (21.7) 19 (20.9) 2 (22.2) 15 (22.7)
 mofetil
 Tacrolimus 6 (3.6) 3 (3.3) 0 3 (4.5)
 Ciclosporin 3 (1.8) 2 (2.2) 0 1 (1.5)
Biologics 58 (34.9) 43 (47.3) 5 (55.6) 10 (15.2)
 Adalimumab 52 (31.3) 38 (41.8) 5 (55.6) 9 (13.6)
 Infliximab 19 (11.4) 14 (15.4) 4 (44.4) 1 (1.5)
 Abatacept 3 (1.8) 3 (1.8) 0 0
 Tocilizumab 2 (1.2) 2 (1.2) 0 0
  1. At presentation 118 eyes JIA, 11 other associated systemic diseases and 105 idiopathic